Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Category

Innovative medicines and medical devices

New therapeutics and devices as they move from approval toward funded access. These stories cover what is launching, what it costs and whether systems are prepared to pay for it.

405 articles in this topic.

Articles in this category

FDA Rejects Ivonescimab Lung Cancer Treatment Over Survival Gap

11/17/2026

FDA Rejects Ivonescimab Lung Cancer Treatment Over Survival Gap

FDA rejects ivonescimab lung cancer treatment: the trial slowed progression, but the overall survival benefit did not reach statistical significance.
Read Article →
NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer

11/16/2026

NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer

NICE draft guidance recommends Cytosponge and EndoSign to help detect oesophageal cancer and Barrett's oesophagus. The tests need no sedation and can be done outside hospital. #SyenzaNews #MarketAccess #HealthTech
Read Article →
NHLS Governance Crisis Reaches Parliament With R1.8 Billion in Irregular Spending

11/13/2026

NHLS Governance Crisis Reaches Parliament With R1.8 Billion in Irregular Spending

The NHLS governance crisis reached Parliament with R1.8 billion in irregular spending, an interim board and a disputed IP Capital consultancy.
Read Article →
US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%

11/12/2026

US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%

A preprint led by Thomas Hwang models how German price changes affect US Medicaid MFN savings and German statutory health insurance spending.
Read Article →
EMA Draft Guideline on Predictive Biomarker Assays Opens Public Consultation to 31 March 2027

11/12/2026

EMA Draft Guideline on Predictive Biomarker Assays Opens Public Consultation to 31 March 2027

The European Medicines Agency has opened public consultation on its draft guideline on predictive biomarker assays. Comments are accepted from 9 November 2026 until 31 March 2027.
Read Article →
Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo

11/10/2026

Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo

The FDA approved Sunharbo (asundexian), the first factor XIa inhibitor for stroke prevention, for adults after a recent ischemic stroke or high-risk TIA. #SyenzaNews #MarketAccess
Read Article →
Enzutrix Patent Dispute Heads to Constitutional Court: Hearing Set for 23 November

11/10/2026

Enzutrix Patent Dispute Heads to Constitutional Court: Hearing Set for 23 November

The Enzutrix patent dispute goes to South Africa's Constitutional Court on 23 November 2026. UC and Astellas are pursuing damages over the generic prostate cancer drug, while Eurolab argues the patent was never validly obtained. #SyenzaNews #MarketAccess
Read Article →
CMS Finalizes GLOBE Model Drug Pricing for Medicare Part B Drugs

11/9/2026

CMS Finalizes GLOBE Model Drug Pricing for Medicare Part B Drugs

CMS finalizes the GLOBE Model drug pricing rule, benchmarking Medicare Part B drug rebates against international prices from April 2027. #SyenzaNews #MarketAccess
Read Article →
Medicare drug price negotiation: CMS sets permanent rules

11/9/2026

Medicare drug price negotiation: CMS sets permanent rules

The final rule also covers a temporary price floor for small biotech drugs and Part D plan payments to dispensing entities. #SyenzaNews #DrugPricing #MarketAccess
Read Article →
Dupilumab Chronic Spontaneous Urticaria: G-BA Finds No Proven Added Benefit

11/6/2026

Dupilumab Chronic Spontaneous Urticaria: G-BA Finds No Proven Added Benefit

The G-BA has found no proven added benefit for dupilumab in chronic spontaneous urticaria, compared with omalizumab plus second-generation H1 antihistamines.
Read Article →
FDA Potency Assurance Guidance: What It Asks of Cell and Gene Therapy Makers

11/3/2026

FDA Potency Assurance Guidance: What It Asks of Cell and Gene Therapy Makers

FDA has finalized its potency assurance guidance for cell and gene therapy products. It covers lot-release testing, potency assays, acceptance criteria and how sponsors should build a strategy from the IND stage onward. #SyenzaNews #CellAndGeneTherapy #FDA
Read Article →
FDA Grants Accelerated Approval to Voceryq for Recurrent Respiratory Papillomatosis

11/2/2026

FDA Grants Accelerated Approval to Voceryq for Recurrent Respiratory Papillomatosis

The FDA has granted accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy in the US, for adults with recurrent respiratory papillomatosis.
Read Article →

Related topics